Dizal Jiangsu Pharmaceutical (SHA:688192) completed patient enrollment for the Phase III clinical trial of Sunvozertinib as a treatment for lung cancer, according to a Shanghai bourse filing on Friday.
The drug will be tested against platinum-based chemotherapy on advanced non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertion mutations.
The trial is a global multi-center confirmatory study held across 16 countries and regions, including China, the US, and Europe, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.